Molecular Profiling of Acute and Chronic Rejections of Renal Allografts
Table 1
Basic patient characteristics.
AMRa
TCMRb
CAMR
CTCMR
N
9
10
13
9
Age
39.56 ± 9.91
49.63 ± 13.96
50.13 ± 11.63
52.60 ± 14.80
Female gender
1 [11.1%]
2 [20.0%]
5 [38.5%]
3 [33.3%]
HLA mismatches: total
4.0 ± 1.3
3.6 ± 1.1
3.4 ± 1.2
3.1 ± 1.1
HLA-A
1.4 ± 0.5
1.2 ± 0.7
1.2 ± 0.7
1.0 ± 0.5
HLA-B
1.5 ± 0.8
1.6 ± 0.5
1.3 ± 0.6
1.2 ± 0.4
HLA-DR
1.1 ± 0.6
0.8 ± 0.4
1.0 ± 0.6
0.9 ± 0.6
PRA at Tx [%]
17.4 ± 22.0
17.3 ± 36.0
17.5 ± 21.9
13.7 ± 12.1
IS: triple therapy based on FK
9 [100%]
10 [100%]
7c [53.8%]
8 [88.9%]
triple therapy based on CsA
0 [0.0%]
0 [0.0%]
4 [30.8%]
0 [0.0%]
mTORi
0 [0.0%]
0 [0.0%]
1 [7.7%]
1 [11.1%]
other
0 [0.0%]
0 [0.0%]
1 [7.7%]
0 [0.0%]
First/second/third/fifth transplants
1/6/1/1d
8/2/0/0
8/4/1/0
7/1/1/0
Induction therapy
9 [100%]
3 [30.0%]
5 [38.5%]
3 [33.3%]
Time to biopsy (months)
91.81 ± 66.99e
33.84 ± 46.65e
(days)
12 ± 4f
8 ± 3f
sCr at Bx (µmol/L)
358.07 ± 148.55
398.66 ± 210.44
213.47 ± 105.15
272.99 ± 98.74
eGFR at Bx (mL/s/1.73 m2)
0.34 ± 0.16
0.36 ± 0.26
0.49 ± 0.22
0.34 ± 0.11
Proteinuria at Bx (g/day)
1.77 ± 1.43
2.26 ±1.94
2.8 ± 3.9
1.3 ± 1.1
C4d +
9 [100%]
0 [0.0%]
13 [100%]
0 [0.0%]
Graft loss during the followup (n)
1 [11.1%]
2 [20.0%]
4 [30.8%]
3 [33.3%]
Continuous variables are means ± SD.
aIncluding combined AMR and TCMR ().
bType IA (), IIA (), IB (), and IIB ().
cSignificantly fewer FK treatment than in other groups ().
dSignificantly more retransplantation in AMR ().
eNo significant difference between CAMR and CTCMR.
fSignificantly longer time to rejection in AMR compared to TCMR ().
